MYC protein interactors in gene transcription and cancer
The transcription factor and oncoprotein MYC is a potent driver of many human cancers and
can regulate numerous biological activities that contribute to tumorigenesis. How a single …
can regulate numerous biological activities that contribute to tumorigenesis. How a single …
Therapeutic inhibition of Myc in cancer. Structural bases and computer-aided drug discovery approaches
LA Carabet, PS Rennie, A Cherkasov - International journal of molecular …, 2018 - mdpi.com
Myc (avian myelocytomatosis viral oncogene homolog) represents one of the most sought
after drug targets in cancer. Myc transcription factor is an essential regulator of cell growth …
after drug targets in cancer. Myc transcription factor is an essential regulator of cell growth …
A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer
Increased expression of the full-length androgen receptor (AR-FL) and AR splice variants
(AR-Vs) drives the progression of castration-resistant prostate cancer (CRPC). The levels of …
(AR-Vs) drives the progression of castration-resistant prostate cancer (CRPC). The levels of …
[HTML][HTML] Drugging the 'undruggable'. Therapeutic targeting of protein–DNA interactions with the use of computer-aided drug discovery methods
Transcription factors (TFs) act as major oncodrivers in many cancers and are frequently
regarded as high-value therapeutic targets. The functionality of TFs relies on direct protein …
regarded as high-value therapeutic targets. The functionality of TFs relies on direct protein …
MYC the oncogene from hell: Novel opportunities for cancer therapy
Cancer comprises a heterogeneous disease, characterized by diverse features such as
constitutive expression of oncogenes and/or downregulation of tumor suppressor genes …
constitutive expression of oncogenes and/or downregulation of tumor suppressor genes …
ETS transcription factors as emerging drug targets in cancer
The ETS family of proteins consists of 28 transcription factors, many of which have been
implicated in development and progression of a variety of cancers. While one family …
implicated in development and progression of a variety of cancers. While one family …
Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability
R Yao, M Zhang, J Zhou, L Liu, Y Zhang, J Gao… - Cell Communication and …, 2022 - Springer
Abstract Background Transcription factor c-Myc plays a critical role in various physiological
and pathological events. c-Myc gene rearrangement is closely associated with multiple …
and pathological events. c-Myc gene rearrangement is closely associated with multiple …
The implication of topoisomerase II inhibitors in synthetic lethality for cancer therapy
VM Matias-Barrios, X Dong - Pharmaceuticals, 2023 - mdpi.com
DNA topoisomerase II (Top2) is essential for all eukaryotic cells in the regulation of DNA
topology through the generation of temporary double-strand breaks. Cancer cells acquire …
topology through the generation of temporary double-strand breaks. Cancer cells acquire …
The slow but steady rise of binding free energy calculations in drug discovery
H Xu - Journal of Computer-Aided Molecular Design, 2023 - Springer
Binding free energy calculations are increasingly used in drug discovery research to predict
protein-ligand binding affinities and to prioritize candidate drug molecules accordingly. It has …
protein-ligand binding affinities and to prioritize candidate drug molecules accordingly. It has …
Turning up the heat on MYC: progress in small-molecule inhibitors
MYC is a highly validated oncogenic transcription factor and cancer target. However, the
disordered nature of this protein has made it a challenging target, with no clinical stage …
disordered nature of this protein has made it a challenging target, with no clinical stage …